Drug Profile
Tocilizumab biosimilar - Dr Reddys Laboratories
Alternative Names: DRL-TC; DRL_TCLatest Information Update: 08 Jun 2023
Price :
$50
*
At a glance
- Originator Dr Reddys Laboratories
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Rheumatoid arthritis
- Phase I Giant cell arteritis
Most Recent Events
- 06 Jun 2023 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) (IV) before June 2023
- 06 Jun 2023 Dr Reddys Laboratories completes a phase I trial in Rheumatoid Arthritis in (IV)
- 04 May 2023 Dr Reddys Laboratories completes a phase I trial in Rheumatoid Arthritis and Giant Cell Arteritis (In volunteers) in New Zealand, Australia and India (SC) (NCT04885829)